<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338779</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN507ST</org_study_id>
    <nct_id>NCT01338779</nct_id>
    <nct_alias>NCT00083655</nct_alias>
  </id_info>
  <brief_title>Study of Tolerant Kidney Transplant Recipients</brief_title>
  <acronym>FACTOR</acronym>
  <official_title>Identification and Mechanistic Investigations of Tolerant Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multi-center (observational) registry study is to establish a database of
      clinical and laboratory information that may help to identify any unique characteristics of
      tolerant participants that differ from participants who reject their kidney after
      discontinuing immunosuppressive drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following kidney (renal) transplantation, one possible complication is rejection of the new
      kidney. This occurs as a results of the body's immune system attacking (or rejecting) the
      newly transplanted kidney. After transplant, medicines known as &quot;immunosuppressive&quot; or
      &quot;anti-rejection&quot; drugs are given to transplant recipients to help prevent rejection of the
      transplanted kidney. If a transplant recipient stops taking these medicines, they almost
      always reject their transplanted kidney. However, in some exceptionally rare instances,
      transplant recipients who stop taking these drugs do not reject their kidney, and the kidney
      keeps working. The recipients are said at that point to &quot;tolerate&quot; the transplanted kidney,
      and this condition is referred to as &quot;tolerance&quot;.

      In this study, participants will be asked to provide consent for the collection of extensive
      demographic and clinical information; medical histories; and blood and urine samples. Blood
      and urine samples collected will be used to perform specific assays to help define mechanisms
      of tolerance.

      Originally the study included 11 groups as listed; however, at present only groups 1,4, and 8
      remain active. Whereas the initial study duration was 6 years, this was extended to 11 years
      in order to follow over more extended time a B cell signature identified for tolerant kidney
      subjects and how this signature may change. (Refer to publications section: Newell, Kirk et
      al, J Clin Invest. 2010).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To identify individuals who have received a kidney transplant and who have achieved a state of immune tolerance to graft</measure>
    <time_frame>0 to 11 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To create an electronic registry of data on the tolerant and comparison groups that will serve as the basis for statistical analyses</measure>
    <time_frame>0 to 11 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To use data from the registry to perform classical tests of hypotheses regarding the establishment of immune tolerance</measure>
    <time_frame>0 to 11 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To use data from the registry to create and assess predictive statistical models to model such variables as clinical features, duration of tolerant state, and time to onset of immune sensitization</measure>
    <time_frame>0 to 11 years</time_frame>
  </primary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Actual">197</enrollment>
  <condition>Transplant Rejection</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Renal Transplantation</condition>
  <condition>Renal Transplant</condition>
  <condition>Transplant Tolerance</condition>
  <arm_group>
    <arm_group_label>Group 1 - kidney tolerant</arm_group_label>
    <description>Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - acceptor</arm_group_label>
    <description>Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) &lt; 40 mL/min and/or creatinine &gt; 50% above baseline value, and thus did not qualify for group 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - kidney graft loss</arm_group_label>
    <description>Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - kidney monotherapy</arm_group_label>
    <description>Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 - kidney standard immunotherapy</arm_group_label>
    <description>Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 - kidney chronic rejector</arm_group_label>
    <description>Enrollment for group 6 is closed. Chronic allograft nephropathy group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7 - kidney identical twin</arm_group_label>
    <description>Enrollment for group 7 is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8 - living kidney donors</arm_group_label>
    <description>Corresponding to recipients in group 1 or 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9 - healthy controls</arm_group_label>
    <description>Enrollment for group 9 is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10 - liver tolerant</arm_group_label>
    <description>Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11 - liver standard immunotherapy</arm_group_label>
    <description>Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine and tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Primary Care Clinics

          -  Major Kidney (Renal) Transplant Programs
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a renal transplant recipient or living donor

          -  Meet the criteria for inclusion in one of the study enrollment groups

          -  Provide informed consent

        Exclusion Criteria:

          -  AIDS [includes all HIV-infected persons who have less than 200 cells/mm(3) CD4+
             T-lymphocytes/microL, or a CD4+ T-lymphocyte/micro liter or a CD4+ T-lymphocyte
             percent of total lymphocytes less than 14, or who have been diagnosed with an
             AIDS-defining condition as defined by the Centers for Disease Control and Prevention
             (CDC)

          -  Current malignancy requiring recent surgery, ongoing chemotherapy or radiation

          -  Acute systemic infections within 30 days prior to enrollment

          -  Pregnancy

          -  Transplant of another organ

        Note: Patients meeting any of the exclusion criteria, if identified to have been clinically
        tolerant prior to the occurrence of the excluding condition, will be enrolled and
        demographic data collected for the registry; however, the decision as to whether or not to
        collect blood, urine, and tissue samples will be deferred until the participant's condition
        improves and the clinically tolerant state persists.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Newell, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network (ITN)</description>
  </link>
  <reference>
    <citation>Schr√∂ppel B, Heeger PS. Gazing into a crystal ball to predict kidney transplant outcome. J Clin Invest. 2010 Jun;120(6):1803-6. doi: 10.1172/JCI43286. Epub 2010 May 24.</citation>
    <PMID>20501950</PMID>
  </reference>
  <results_reference>
    <citation>Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL; Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010 Jun;120(6):1836-47. doi: 10.1172/JCI39933. Epub 2010 May 24.</citation>
    <PMID>20501946</PMID>
  </results_reference>
  <results_reference>
    <citation>Haynes LD, Jankowska-Gan E, Sheka A, Keller MR, Hernandez-Fuentes MP, Lechler RI, Seyfert-Margolis V, Turka LA, Newell KA, Burlingham WJ. Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients. Am J Transplant. 2012 Mar;12(3):640-8. doi: 10.1111/j.1600-6143.2011.03869.x. Epub 2011 Dec 7.</citation>
    <PMID>22151236</PMID>
  </results_reference>
  <results_reference>
    <citation>Newell KA, Asare A, Sanz I, Wei C, Rosenberg A, Gao Z, Kanaparthi S, Asare S, Lim N, Stahly M, Howell M, Knechtle S, Kirk A, Marks WH, Kawai T, Spitzer T, Tolkoff-Rubin N, Sykes M, Sachs DH, Cosimi AB, Burlingham WJ, Phippard D, Turka LA. Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients. Am J Transplant. 2015 Nov;15(11):2908-20. doi: 10.1111/ajt.13480. Epub 2015 Oct 13.</citation>
    <PMID>26461968</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu J, Steck AK, Babu S, Yu L, Miao D, McFann K, Hutton J, Eisenbarth GS, Klingensmith G. Single nucleotide transcription factor 7-like 2 (TCF7L2) gene polymorphisms in antiislet autoantibody-negative patients at onset of diabetes. J Clin Endocrinol Metab. 2009 Feb;94(2):504-10. doi: 10.1210/jc.2007-2694. Epub 2008 Dec 2.</citation>
    <PMID>19050058</PMID>
  </results_reference>
  <results_reference>
    <citation>Brennan DC, Shannon MB, Koch MJ, Polonsky KS, Desai N, Shapiro J. Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation. 2004 Jul 15;78(1):172-3.</citation>
    <PMID>15257060</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerance</keyword>
  <keyword>Renal</keyword>
  <keyword>Allograft</keyword>
  <keyword>B Cell Signature</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participant level data access is available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>ImmPort Study ID: SDY546</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY546</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>ImmPort Study ID: SDY546</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY546</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>ImmPort Study ID: SDY546</doc_id>
      <doc_type>Study summary,-design, demographics,mechanistic assays,-study files et al.</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY546</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>Study ID: FACTOR/ITN507ST</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN507STAJT/Study%20Data/begin.view</doc_url>
      <doc_comment>FACTOR/ITN507ST is the Study Identifier in the ITN TrialShare Clinical Trials Research Portal.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>Study ID: FACTOR/ITN507ST</doc_id>
      <doc_type>Original articles w/data and reports; abstracts et al.</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN507STAJT/Study%20Data/begin.view</doc_url>
      <doc_comment>FACTOR/ITN507ST is the Study Identifier in the ITN TrialShare Clinical Trials Research Portal.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

